Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements
This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chlo...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacokinetics 1996-10, Vol.31 (4), p.257-274 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 274 |
---|---|
container_issue | 4 |
container_start_page | 257 |
container_title | Clinical pharmacokinetics |
container_volume | 31 |
creator | DUCHARME, J FARINOTTI, R |
description | This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine. |
doi_str_mv | 10.2165/00003088-199631040-00003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78491959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78491959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-d5a573d294bf5e803201851b7b481cab79e989e107c42f7a58b8ecadcf1ffad93</originalsourceid><addsrcrecordid>eNo9kE1PxCAQhonRrOvqTzDhYLxV-SgteDMbV0028aJemymFLNqWFVoT_72sW5fLkHeegcmDEKbkhtFC3JJ0OJEyo0oVnJKcZH_REZpTWqoUs-IYzQmnLBOJOEVnMX4kQjJCZmgmpSpUzufofdm63mlo8XYDoQPtP11vBqcjhr7BnRmg9q2LHfYW603rg_8aE4Hv8MrrMWLf42C06QcMzTf02nTpHs_RiYU2moupLtDb6uF1-ZStXx6fl_frTHOihqwRIEreMJXXVhhJOCNUClqXdS6phrpURkllKCl1zmwJQtbSaGi0pdZCo_gCXe_f3e72MnGoOhe1aVvojR9jVcpcUSV2oNyDOvgYg7HVNrgOwk9FSbVTWv0rrQ5K91EavZz-GOvONIfByWHqX019iEmkDcmCiweMs5wpmvNfi1h_RA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78491959</pqid></control><display><type>article</type><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>DUCHARME, J ; FARINOTTI, R</creator><creatorcontrib>DUCHARME, J ; FARINOTTI, R</creatorcontrib><description>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-199631040-00003</identifier><identifier>PMID: 8896943</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimalarials - metabolism ; Antimalarials - pharmacokinetics ; Antiparasitic agents ; Biological and medical sciences ; Chloroquine - metabolism ; Chloroquine - pharmacokinetics ; Humans ; Malaria - drug therapy ; Malaria - metabolism ; Medical sciences ; Pharmacology. Drug treatments ; Stereoisomerism ; Tissue Distribution</subject><ispartof>Clinical pharmacokinetics, 1996-10, Vol.31 (4), p.257-274</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3242914$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8896943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DUCHARME, J</creatorcontrib><creatorcontrib>FARINOTTI, R</creatorcontrib><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</description><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimalarials - metabolism</subject><subject>Antimalarials - pharmacokinetics</subject><subject>Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Chloroquine - metabolism</subject><subject>Chloroquine - pharmacokinetics</subject><subject>Humans</subject><subject>Malaria - drug therapy</subject><subject>Malaria - metabolism</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Stereoisomerism</subject><subject>Tissue Distribution</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PxCAQhonRrOvqTzDhYLxV-SgteDMbV0028aJemymFLNqWFVoT_72sW5fLkHeegcmDEKbkhtFC3JJ0OJEyo0oVnJKcZH_REZpTWqoUs-IYzQmnLBOJOEVnMX4kQjJCZmgmpSpUzufofdm63mlo8XYDoQPtP11vBqcjhr7BnRmg9q2LHfYW603rg_8aE4Hv8MrrMWLf42C06QcMzTf02nTpHs_RiYU2moupLtDb6uF1-ZStXx6fl_frTHOihqwRIEreMJXXVhhJOCNUClqXdS6phrpURkllKCl1zmwJQtbSaGi0pdZCo_gCXe_f3e72MnGoOhe1aVvojR9jVcpcUSV2oNyDOvgYg7HVNrgOwk9FSbVTWv0rrQ5K91EavZz-GOvONIfByWHqX019iEmkDcmCiweMs5wpmvNfi1h_RA</recordid><startdate>19961001</startdate><enddate>19961001</enddate><creator>DUCHARME, J</creator><creator>FARINOTTI, R</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19961001</creationdate><title>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</title><author>DUCHARME, J ; FARINOTTI, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-d5a573d294bf5e803201851b7b481cab79e989e107c42f7a58b8ecadcf1ffad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimalarials - metabolism</topic><topic>Antimalarials - pharmacokinetics</topic><topic>Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Chloroquine - metabolism</topic><topic>Chloroquine - pharmacokinetics</topic><topic>Humans</topic><topic>Malaria - drug therapy</topic><topic>Malaria - metabolism</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Stereoisomerism</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DUCHARME, J</creatorcontrib><creatorcontrib>FARINOTTI, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DUCHARME, J</au><au>FARINOTTI, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>1996-10-01</date><risdate>1996</risdate><volume>31</volume><issue>4</issue><spage>257</spage><epage>274</epage><pages>257-274</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>8896943</pmid><doi>10.2165/00003088-199631040-00003</doi><tpages>18</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0312-5963 |
ispartof | Clinical pharmacokinetics, 1996-10, Vol.31 (4), p.257-274 |
issn | 0312-5963 1179-1926 |
language | eng |
recordid | cdi_proquest_miscellaneous_78491959 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antimalarials - metabolism Antimalarials - pharmacokinetics Antiparasitic agents Biological and medical sciences Chloroquine - metabolism Chloroquine - pharmacokinetics Humans Malaria - drug therapy Malaria - metabolism Medical sciences Pharmacology. Drug treatments Stereoisomerism Tissue Distribution |
title | Clinical pharmacokinetics and metabolism of chloroquine : Focus on recent advancements |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A47%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacokinetics%20and%20metabolism%20of%20chloroquine%20:%20Focus%20on%20recent%20advancements&rft.jtitle=Clinical%20pharmacokinetics&rft.au=DUCHARME,%20J&rft.date=1996-10-01&rft.volume=31&rft.issue=4&rft.spage=257&rft.epage=274&rft.pages=257-274&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-199631040-00003&rft_dat=%3Cproquest_cross%3E78491959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78491959&rft_id=info:pmid/8896943&rfr_iscdi=true |